Grace Therapeutics Stock (NASDAQ:GRCE)

Financials Chart

Previous Close

$2.16

52W Range

$1.75 - $4.97

50D Avg

$2.64

200D Avg

$3.02

Market Cap

$27.98M

Avg Vol (3M)

$64.52K

Beta

1.33

Div Yield

-

GRCE Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Feb 07, 2012

Website

GRCE Performance

GRCE Financial Summary

	Mar 24	Mar 23	Mar 22
Revenue	-	-	-
Operating Income	$-12.85M	$-52.16M	$-15.59M
Net Income	$-12.85M	$-42.43M	$-9.82M
EBITDA	$-11.33M	$-18.12M	$-15.34M
Basic EPS	$-1.73	$-5.71	$-1.62
Diluted EPS	$-1.73	$-5.71	$-1.62

Fiscal year ends in Mar 24 | Currency in USD